A Phase 1b Multi-center Open-label Dose Finding Study of CC-122 in Combination with Sorafenib in Subjects with Unresectable Hepatocellular Carcinoma
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to evaluate the safety of a new experimental medication called CC 122, in combination with sorafenib, which is an approved medication for liver cancer.
Description
The purpose of this study is to evaluate the safety of a new experimental medication called CC 122, in combination with sorafenib, which is an approved medication for liver caner.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
liver cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1408955560
